Remdesivir for the treatment of patients in hospital with COVID-19 in Canada: a randomized controlled trial.

ABSTRACT:

Background

The role of remdesivir in the treatment of patients in hospital with COVID-19 remains ill defined in a global context. The World Health Organization Solidarity randomized controlled trial (RCT) evaluated remdesivir in patients across many countries, with Canada enrolling patients using an expanded data collection format in the Canadian Treatments for COVID-19 (CATCO) trial. We report on the Canadian findings, with additional demographics, characteristics and clinical outcomes, to explore the potential for differential effects across different health care systems.

Methods

We performed an open-label, pragmatic RCT in Canadian hospitals, in conjunction with the Solidarity trial. We randomized patients to 10 days of remdesivir (200 mg intravenously [IV] on day 0, foll

SUBMITTER: Ali K 

PROVIDER: S-EPMC8863204 | biostudies-literature | 2022 Feb

REPOSITORIES: biostudies-literature